Compare EPAM Systems Inc (EPAM) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Pfizer Inc — how do they compare? EPAM Systems Inc trades at $114 (market cap $5.59B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 28.5× EPAM Systems Inc's market cap, and Pfizer Inc pays a 6.14% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Pfizer Inc for 158 Days on average.
| EPAM | PFE | |
|---|---|---|
Market Cap | $5.59B | $159.59B |
Volume | 551,846 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $221.40 | $29.02 |
52-Week Low | $76.04 | $23.67 |
Typical Hold Time | 37 Days | 158 Days |
Enterprise Value | $4.95B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $108.32, down 0.91% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $3.38, beating estimates, and maintains strong profitability with a net margin of 7.15%. Recent news highlights partnerships in cloud security and AI-native revenue growth exceeding 11%.
The stock appears undervalued with a P/E of 14.7 and consensus price target of $119.00, offering potential upside. However, risks include slower North American growth and AI disruption to legacy services. Analyst sentiment is mixed with 59% buy ratings but recent institutional selling adds caution.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
